EGFR and cancer: Overexpression and hyperactivation/hyper-phosphorylation of EGFR has been linked to anoikis resistance in a range of cancers, including hepatocellular carcinoma (Lim et al., 2020), GBME (Talukdar et al., 2018), breast (Oberst et al., 2008), lung (Chunhacha et al., 2013) and prostate cancer (Giannoni et al., 2009).